BUSINESS

• Abbott Japan Takes Over Marketing Approval for Duphaston from Daiichi Sankyo
  April 2, 2014

• Kyowa Kirin Files Nesp in Japan for Anemia in Myelodysplastic Syndrome
  April 2, 2014

• Japan Vaccine Files NDA for Pneumococcal Conjugate Vaccine in Japan
  April 2, 2014

• US Biotech NPS Takes Aim at Japan Debut around 2017
  April 1, 2014

• Torii Puts Off Launch of Sublingual Hay Fever Drug
  April 1, 2014

• Otsuka Acquires Rights for Dacogen from Eisai US Subsidiary
  April 1, 2014

• Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
  March 31, 2014

• AnGes MG to Procure 500 Million Yen through Allocation of New Shares to Third Party, to Invest in Orphan Drug Licensing
  March 31, 2014

• Suglat Tops February “Mind Share” Ranking in GP Market　
  March 31, 2014

• Uniform Pricing of Generics into 3 Price Brackets Will Make It More Difficult to Set Invoice Prices: Pres. Yoshiwaka of Daiichi Sankyo Espha
  March 28, 2014

• Takeda, Otsuka to Copromote Takeda’s Novel Acid-Related Disease Treatment Vonoprazan
  March 28, 2014

• Cetirizine Generics to Carry 3 Prices, Down from 13: Jiho Tally
  March 27, 2014

• Qualified Bidders Selected in 1st Qol-Led Open Tender
  March 27, 2014

• PII Study of Anti-PCSK9 Antibody in Japanese Patients Meets Primary Endpoint: Amgen Astellas
  March 27, 2014

• Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho
  March 26, 2014

• DSP’s Antipsychotic Agent Latuda Gets OK in Australia
  March 26, 2014

• MHLW Approves Toyama Chemical’s Novel Anti-Influenza Drug Avigan Tablets
  March 26, 2014

• Mitsui Becomes Largest Shareholder of Fuji Pharma through Capital, Business Alliance
  March 26, 2014

• Otsuka’s Samsca Approved in Japan as World’s 1st ADPKD Treatment
  March 26, 2014

• Novartis Will Not Sell Rasilamlo Blood Pressure Drug in Japan
  March 26, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 571
• 572
• 573
• 574
• 575
• 576
• 577
• 578
• 579
• …
• Next ›
• 最終 »